New Parkinson’s drug approved in the US: What does it do differently?
The FDA approved a new once-daily Parkinson’s pill in the dopamine agonist class, designed to selectively target receptors studied for decades; in trials, AbbVie’s drug improved movement and daily functioning
We haven't written up this one. Ynetnews Culture has the full story — the link below goes straight to it.